← 返回

高危 DCIS 进展的肿瘤微环境决定因素

英文原题:Tumor microenvironmental determinants of high-risk DCIS progression.

查看英文原题

Tumor microenvironmental determinants of high-risk DCIS progression.

PubMed 2024/05/09(内容时间) Res Sq

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

原位导管癌(DCIS)是乳腺导管树内形态学可识别的一组肿瘤,病灶在活检发现部位或附近存在进展为浸润癌的风险。然而,未经治疗的 DCIS 仅有 15%–45% 会进展为浸润癌,因此了解阻止进展的机制对于避免过度治疗并制定替代疗法和预防策略至关重要。

本研究旨在描述体积较大但仍局限于 DCIS 的高危病变肿瘤微环境和分子特征。所有患者的 DCIS 病灶均>5 cm,且至少伴有一项其他高危特征:年龄较轻(<45 岁)、核分级高、激素受体阴性、HER2 阳性、存在粉刺样坏死或可触及肿块。采用多重免疫荧光表征肿瘤免疫微环境,鉴定免疫细胞及其在导管和基质中的空间关系。通过基因拷贝数分析和全外显子 DNA 测序鉴定突变负荷和驱动突变,并进行全转录组/基因表达定量分析。DCIS 基因组中拷贝数变异(CNA)所占比例与复发(DCIS 或浸润癌)无关联。在该高危队列中,乳腺癌驱动基因 PIK3CA 和 TP53 突变(尤其错义突变)较常见,占所评估病灶的 47%。

与野生型病灶相比,TP53 突变病灶 TIL 密度较高(P=0.0079),但 PIK3CA 突变病灶无此差异(P=0.44)。免疫浸润与激素受体状态负相关,与 HER2 表达正相关。CD3+CD8− T 细胞水平高与任何后续复发(DCIS 或浸润癌)风险较低相关;CD3+Foxp3+ Treg 水平高则与不良结局相关。免疫细胞与肿瘤细胞空间邻近分析显示,T 细胞与肿瘤细胞靠近与任何复发及浸润癌复发结局较好相关。有趣的是,DCIS 病灶中肌上皮连续性(受累导管周围肌上皮细胞间距)显著低于正常组织(P=0.0002)和非典型导管增生(P=0.011)。基因集富集分析发现多个免疫通路与低肌上皮连续性相关,且低连续性评分与较好结局相关,提示肌上皮层间隙可能使免疫浸润细胞得以接近并与肿瘤细胞相互作用。

本研究表明,DCIS 免疫微环境特征,特别是肿瘤细胞与 T 细胞的空间邻近性及肌上皮连续性,是疾病进展的重要决定因素。

展开英文摘要原文

Ductal carcinoma in situ (DCIS) constitutes an array of morphologically recognized intraductal neoplasms in the mammary ductal tree defined by an increased risk for subsequent invasive carcinomas at or near the site of biopsy detection.

However, only 15-45% of untreated DCIS cases progress to invasive cancer, so understanding mechanisms that prevent progression is key to avoid overtreatment and provides a basis for alternative therapies and prevention.

This study was designed to characterize the tumor microenvironment and molecular profile of high-risk DCIS that grew to a large size but remained as DCIS. All patients had DCIS lesions >5cm in size with at least one additional high-risk feature: young age (<45 years), high nuclear grade, hormone receptor negativity, HER2 positivity, the presence of comedonecrosis, or a palpable mass. The tumor immune microenvironment was characterized using multiplex immunofluorescence to identify immune cells and their spatial relationships within the ducts and stroma. Gene copy number analysis and whole exome DNA sequencing identified the mutational burden and driver mutations, and quantitative whole-transcriptome/gene expression analyses were performed. There was no association between the percent of the DCIS genome characterized by copy number variants (CNAs) and recurrence events (DCIS or invasive). Mutations, especially missense mutations, in the breast cancer driver genes PIK3CA and TP53 were common in this high-risk DCIS cohort (47% of evaluated lesions). Tumor infiltrating lymphocyte (TIL) density was higher in DCIS lesions with TP53 mutations (p=0.

0079) compared to wildtype lesions, but not in lesions with PIK3CA mutations (p=0. 44). Immune infiltrates were negatively associated with hormone receptor status and positively associated with HER2 expression. High levels of CD3+CD8- T cells were associated with good outcomes with respect to any subsequent recurrence (DCIS or invasive cancer), whereas high levels of CD3+Foxp3+ Treg cells were associated with poor outcomes. Spatial proximity analyses of immune cells and tumor cells demonstrated that close proximity of T cells with tumor cells was associated with good outcomes with respect to any recurrence as well as invasive recurrences.

Interestingly, we found that myoepithelial continuity (distance between myoepithelial cells surrounding the involved ducts) was significantly lower in DCIS lesions compared to normal tissue (p=0. 0002) or to atypical ductal hyperplasia (p=0. 011). Gene set enrichment analysis identified several immune pathways associated with low myoepithelial continuity and a low myoepithelial continuity score was associated with better outcomes, suggesting that gaps in the myoepithelial layer may allow access/interactions between immune infiltrates and tumor cells.

Our study demonstrates the immune microenvironment of DCIS, in particular the spatial proximity of tumor cells and T cells, and myoepithelial continuity are important determinants for progression of disease.

论文信息

作者
Borowsky A、Glencer A、Ramalingam K、Schindler N、Mori H、Ghule P、Lee K、Nachmanson D
第一作者单位
UC Davis.
通讯作者单位
UCSF.
文献类型
预印本
期刊
Research square2024 May 9
原文标识
PubMed 38766192 · DOI 10.21203/rs.3.rs-4126092/v1